Hyun-Sung Lee, MD, PhD
Division of Thoracic Surgery, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX, USA
Dr. Hyun-Sung Lee has more than 10 years of experience in studying lung cancer and esophageal cancer as a thoracic surgeon, 3 years of research experience in the Department of Systems Biology at UT MD Anderson Cancer Center, and 4 years of immunology experience in the Michael E. DeBakey Department of Surgery at Baylor College of Medicine. He is particularly enthusiastic about “Systems Immunology” in the field of immuno-oncology with specific experience in comprehensively integrating high dimensional single cell time-of-flight mass cytometry (CyTOF), imaging mass cytometry (IMC), mass spectrometry, and next generation sequencing data. He has recently generated a comprehensive atlas of the immunologic cellular networks within human malignant pleural mesothelioma (MPM) using CyTOF. Dr. Lee has applied innovative immunoproteomic and immunogenomic approaches to this framework to understand mechanisms underlying clinical outcomes and response to immunotherapy in this disease. He continues to characterize and unravel the cellular immune network by analyzing human and mouse CyTOF and IMC data, and correlating immune composition with immunogenomic determinants in order to predict clinical prognosis and response to immune checkpoint inhibitors. He is also conducting systems immunologic analyses of a mouse model of cancer, which will provide a rationale for human studies along these lines and can shed light on the development of novel immunotherapeutic molecules targeting immunotherapy-resistant patients. His strongest expertise lies in clinical implication and resources of thoracic oncology as a bridging role for the translational research. Dr. Lee's overarching goals are to identify potential therapeutic targets and to develop strong prognostic or predictive determinants for management of thoracic cancer including lung cancer, esophageal cancer, thymic epithelial tumors, and MPM by applying “comprehensive and integrated systems immunology” approaches.
Terms of Appointment: Nov 2019 – Oct 2021